Literature DB >> 19861588

The effect of different patterns of growth hormone administration on the IGF axis and somatic and skeletal growth of the dwarf rat.

Melissa Westwood1, Arfa R Maqsood, Mattea Solomon, Andrew J Whatmore, Julian R E Davis, Robert C Baxter, Evelien F Gevers, Iain C A F Robinson, Peter E Clayton.   

Abstract

Normal childhood growth is determined by ultradian and infradian variations in GH secretion, yet GH treatment of children with short stature is restricted to daily fixed doses. We have used GH-deficient dwarf rats to determine whether variable GH dose regimens promote growth more effectively than fixed doses. Animals were treated with saline or 4.2 mg of recombinant bovine GH given as 1) 700 microg/wk in 100 microg/day doses, 2) alternating weekly doses of 966 (138 microg/day) or 434 microg (62 microg/day), or 3) 700 microg/wk in randomized daily doses (5-250 microg/day). Body weight and length were measured weekly. Femur and tibia lengths and internal organ, fat pad, and muscle weights were recorded at the end of the study (6 wk); blood was collected for IGF axis measurements. GH promoted femur [F(3,60) = 14.67, P < 0.05], tibia [F(3,60) = 14.90, P < 0.05], muscle [F(3,60) = 10.37, P < 0.05], and organ growth [liver: F(3,60) = 9.30, P < 0.05; kidney: F(3,60) = 2.82, P < 0.05] and an increase in serum IGF-I [F(3,60) = 9.18, P < 0.05] and IGFBP-3 [F(3,60) = 6.70, P < 0.05] levels. IGF-I levels correlated with final weight (r = 0.45, P < 0.05) and length (r = 0.284, P < 0.05) in the whole cohort, but within each group, growth parameters correlated with serum IGF-I only in animals treated with random GH doses. The variable regimens promoted femur length (P < 0.05) and muscle (P < 0.05) and kidney (P < 0.05) weight more effectively than treatment with the fixed regimen. This study demonstrates that aspects of growth are improved following introduction of infradian variation to GH treatment in a GH-deficient model. The data suggest that varying the pattern of GH doses administered to children may enhance growth performance without increasing the overall GH dose.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19861588      PMCID: PMC2838527          DOI: 10.1152/ajpendo.00234.2009

Source DB:  PubMed          Journal:  Am J Physiol Endocrinol Metab        ISSN: 0193-1849            Impact factor:   4.310


  59 in total

Review 1.  The insulin-like growth factors and the lung.

Authors:  A D Stiles; A J D'Ercole
Journal:  Am J Respir Cell Mol Biol       Date:  1990-08       Impact factor: 6.914

2.  The pituitary gland secretes in bursts: appraising the nature of glandular secretory impulses by simultaneous multiple-parameter deconvolution of plasma hormone concentrations.

Authors:  J D Veldhuis; M L Carlson; M L Johnson
Journal:  Proc Natl Acad Sci U S A       Date:  1987-11       Impact factor: 11.205

3.  Pulsatile growth hormone, insulin-like growth factors and antler development in red deer (Cervus elaphus scoticus) stags.

Authors:  J M Suttie; P F Fennessy; I D Corson; F J Laas; S F Crosbie; J H Butler; P D Gluckman
Journal:  J Endocrinol       Date:  1989-05       Impact factor: 4.286

4.  Immunological studies with rat pituitary growth hormone. I. Basic studies with immunodiffusion and antihormone tests.

Authors:  T Hayashida; A N Contopoulos
Journal:  Gen Comp Endocrinol       Date:  1967-10       Impact factor: 2.822

5.  Growth hormone-deficient dwarfism in the rat: a new mutation.

Authors:  H M Charlton; R G Clark; I C Robinson; A E Goff; B S Cox; C Bugnon; B A Bloch
Journal:  J Endocrinol       Date:  1988-10       Impact factor: 4.286

6.  Growth responses in a mutant dwarf rat to human growth hormone and recombinant human insulin-like growth factor I.

Authors:  A Skottner; R G Clark; L Fryklund; I C Robinson
Journal:  Endocrinology       Date:  1989-05       Impact factor: 4.736

Review 7.  Sexual dimorphism in the control of growth hormone secretion.

Authors:  J O Jansson; S Edén; O Isaksson
Journal:  Endocr Rev       Date:  1985       Impact factor: 19.871

8.  Pharmacokinetic and pharmacodynamic characteristics of a long-acting growth hormone (GH) preparation (nutropin depot) in GH-deficient children.

Authors:  S F Kemp; P J Fielder; K M Attie; S L Blethen; E O Reiter; K M Ford; M Marian; L N Dao; H J Lee; P Saenger
Journal:  J Clin Endocrinol Metab       Date:  2004-07       Impact factor: 5.958

9.  Effects of continuous infusion of insulin-like growth factor I and II, alone and in combination with thyroxine or growth hormone, on the neonatal hypophysectomized rat.

Authors:  G F Glasscock; A N Hein; J A Miller; R L Hintz; R G Rosenfeld
Journal:  Endocrinology       Date:  1992-01       Impact factor: 4.736

10.  Different effects of intermittent and continuous growth hormone (GH) administration on serum somatomedin-C/insulin-like growth factor I and liver GH receptors in hypophysectomized rats.

Authors:  D Maiter; L E Underwood; M Maes; M L Davenport; J M Ketelslegers
Journal:  Endocrinology       Date:  1988-08       Impact factor: 4.736

View more
  3 in total

1.  Prenatal dexamethasone exposure potentiates diet-induced hepatosteatosis and decreases plasma IGF-I in a sex-specific fashion.

Authors:  David L Carbone; Damian G Zuloaga; Ryoko Hiroi; Chad D Foradori; Marie E Legare; Robert J Handa
Journal:  Endocrinology       Date:  2011-11-08       Impact factor: 4.736

2.  Effects of long-term experimental diabetes on adrenal gland growth and phosphoribosyl pyrophosphate formation in growth hormone-deficient dwarf rats.

Authors:  Sirilaksana Kunjara; A Leslie Greenbaum; Patricia McLean; Henning Grønbaek; Allan Flyvbjerg
Journal:  Int J Exp Pathol       Date:  2012-06       Impact factor: 1.925

Review 3.  Advantages and Disadvantages of Different Treatment Methods in Achondroplasia: A Review.

Authors:  Wiktoria Wrobel; Emilia Pach; Iwona Ben-Skowronek
Journal:  Int J Mol Sci       Date:  2021-05-25       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.